Neil Gibson

Neil W.
Gibson currently serves as Independent Director at Shattuck Labs, Inc. since 2016, Lead Independent Director at Instil Bio, Inc. since 2021, Director at Cullinan MICA, Inc. since 2020, and Director at both Causeway Therapeutics Ltd. and Cullinan Mica Corp.
Former roles include President & Chief Executive Officer at Cullinan Mica Corp.
from 2017 to 2020, President & Co-Chief Executive Officer at Adanate, Inc. from 2017 to 2021, Independent Director at TCR² Therapeutics, Inc. from 2018 to 2023, Director at CytoSen Therapeutics, Inc. from 2016 to 2019, Chief Scientific Officer & Vice President at OSI Pharmaceuticals, Inc. from 2001 to 2007, Chief Scientific Officer-Oncology Research Unit at Pfizer Inc. from 2007 to 2011, Chief Scientific Officer at Regulus Therapeutics, Inc. from 2011 to 2015, Chief Development Officer & Senior Vice President at BioAtla, Inc. from 2015 to 2016, Chief Scientific Officer & Senior Vice President at COI Pharmaceuticals, Inc. from 2016 to 2021, Director-Cancer Research at Bayer AG in 2001, Associate Professor at the University of Southern California, Chief Scientific Officer at Silarus Therapeutics, Inc., President of the British Pharmaceutical Students Association, and President of the British Pharmaceutical Students Association.
Education includes undergraduate studies at the University of Strathclyde and a doctorate from the University of Aston conferred in 1982.